Jazz Pharmaceuticals (NASDAQ:JAZZ) EVP Sells $1,204,573.34 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) EVP Robert Iannone sold 7,159 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the sale, the executive vice president owned 72,628 shares of the company’s stock, valued at approximately $12,220,387.28. This trade represents a 8.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $176.93 on Friday. The firm has a market cap of $10.75 billion, a price-to-earnings ratio of -26.29, a PEG ratio of 8.49 and a beta of 0.29. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The business’s 50 day moving average is $138.86 and its two-hundred day moving average is $122.36. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share for the quarter, topping analysts’ consensus estimates of $5.87 by $2.26. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $6.54 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. Analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $127,344,000. Nuveen LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth about $62,362,000. Fuller & Thaler Asset Management Inc. lifted its position in Jazz Pharmaceuticals by 41.7% in the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock valued at $165,245,000 after purchasing an additional 391,660 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Jazz Pharmaceuticals by 592.1% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock valued at $57,523,000 after purchasing an additional 373,383 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after purchasing an additional 304,463 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company upped their target price on shares of Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 28th. Bank of America increased their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a report on Tuesday. The Goldman Sachs Group boosted their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Finally, Truist Financial raised their price objective on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Jazz Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $195.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.